Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Keratosis, Actinic 5Carcinoma, Squamous Cell 2Squamous Intraepithelial Lesions 1Radiodermatitis 1Psoriasis 1Neoplasms 1Lymphoma, Follicular 1Carcinoma 1Breast Neoplasms 1

Interventions

tofacitinib 7Etanercept 6Methotrexate 3Adalimumab 3secukinumab 2Nivolumab 2sotrastaurin 1sodium luminolate 1ixekizumab 1deucravacitinib 1calcipotriene 1cabozantinib 1baricitinib 1apremilast 1abrocitinib 1Vitamin D 1Vaccines 1Specimen Handling 1Saline Solution 1Platinum Compounds 1Ipilimumab 1Herpes Zoster Vaccine 1Folic Acid 1Fish Oils 1Fatty Acids, Omega-3 1Exercise 1Eicosapentaenoic Acid 1Docosahexaenoic Acids 1Cholecalciferol 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Psoriasis × calcipotriene × Clear all
NCT01582932 2019-01-22

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

Mayne Pharma International Pty Ltd

Phase 1 Completed
36 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡